CONMED Corporation (NYSE: CNMD) today announced that Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference at 10:30...
XRAY vs. CNMD: Which Stock Is the Better Value Option?
CONMED's (CNMD) fourth-quarter earnings gain from higher revenues and strong performance in General Surgery segment. However, high long-term debt remains a concern.
Conmed Corp (NASDAQ:CNMD) traded in a range yesterday that spanned from a low of $103.45 to a high of $112.00. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of...
Conmed (CNMD) delivered earnings and revenue surprises of 1.12% and 0.01%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
UTICA, N.Y. (AP) _ Conmed Corp. (CNMD) on Wednesday reported fourth-quarter earnings of $14.9 million.
CONMED Corporation (NASDAQ: CNMD) today announced that it is transferring the listing of its common stock to the New York Stock Exchange (NYSE) from the NASDAQ Global Market.
CONMED Corporation (Nasdaq: CNMD) today announced financial results for the fourth quarter and full year ended December 31, 2019.
A series of product launches despite the ongoing regulatory hurdles is likely to favor revenues in the medical products space this earnings season.
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CONMED Corporation (NASDAQ: CNMD) today announced that it will report financial results for the fourth quarter and full year 2019 after the market close on Wednesday, January 29, 2020. The...
CONMED Corporation (NASDAQ: CNMD) today announced that Curt R. Hartman, President and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at...
Patterson Companies (PDCO) continues to benefit from robust product portfolio, strong prospects in Animal Health unit and strategic buyouts.
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.
The latest deal is likely to boost HMS Holdings' (HMSY) Payment Integrity solutions business.
Masimo (MASI) raises revenue and earnings guidance for 2019.
PDCO vs. CNMD: Which Stock Is the Better Value Option?
Banking on the three key trends, we zero in on six MedTech stocks that are likely to deliver stellar performance in 2020.
Masimo (MASI) sees a slew of developments in recent times.